BNP Paribas Reduces Healthpeak Properties' Price Target from $24 to $22
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Source: Yahoo Finance
Company Overview: Healthpeak Properties (DOC) has received an average rating of overweight from analysts.
Price Target: The mean price target for Healthpeak Properties is set at $20.88.
Analyst Views on DOC
Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 17.790
Low
16.71
Averages
19.23
High
21.00
Current: 17.790
Low
16.71
Averages
19.23
High
21.00
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. The Company’s segments include Lab, Outpatient medical and continuing care retirement community (CCRC). The Outpatient medical segment owns, operates, and develops outpatient medical buildings, hospitals, and lab buildings. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. Its CCRC segment is a retirement community that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
